Carisma Therapeutics Stock Today
| CARM Stock | 0.42 0 0.95% |
PerformanceInsignificant
| Odds Of DistressVery High
|
Carisma Therapeutics is selling at 0.41600001 as of the 21st of March 2025; that is 0.95% down since the beginning of the trading day. The stock's lowest day price was 0.42. Carisma Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of February 2014 | Category Healthcare | Classification Health Care |
Carisma Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 41.75 M outstanding shares of which 596.46 K shares are currently shorted by private and institutional investors with about 1.03 trading days to cover. More on Carisma Therapeutics
Moving together with Carisma Stock
Moving against Carisma Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Carisma Stock Highlights
| CEO President | Steven Kelly | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SBF 120, CAC All Shares, CAC Mid 60, CAC All Tradable, CAC Mid Small, CAC All-Tradable, CAC All-Tradable Net, SBF 120 Gross, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCarisma Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Carisma Therapeutics' financial leverage. It provides some insight into what part of Carisma Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carisma Therapeutics (CARM) is traded on NASDAQ Exchange in USA. It is located in 3675 Market Street, Philadelphia, PA, United States, 19104 and employs 107 people. Carisma Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.54 M. Carisma Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.75 M outstanding shares of which 596.46 K shares are currently shorted by private and institutional investors with about 1.03 trading days to cover.
Carisma Therapeutics generates negative cash flow from operations
Check Carisma Therapeutics Probability Of Bankruptcy
Ownership AllocationCarisma Therapeutics holds a total of 41.75 Million outstanding shares. Carisma Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Carisma Ownership Details
Carisma Therapeutics Historical Income Statement
Carisma Stock Against Markets
Carisma Therapeutics Corporate Management
| Terry Shields | Senior Resources | Profile | |
| Kenneth Locke | Senior Operations | Profile | |
| MD FACS | Chief Officer | Profile | |
| MBA JD | General Secretary | Profile | |
| Tom Wilton | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share | Quarterly Revenue Growth (0.12) | Return On Assets | Return On Equity |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.